Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDI Rx Licensing Strategy Puts CSO In Competition With Small Manufacturers

Executive Summary

PDI's breach of contract settlement with Auxilium is a result of the contract sales organization's new strategy of competing with small pharmaceutical manufacturers

You may also be interested in...



PDI Combing Urology, Neurology Markets For Licensing/Acquisition Deals

PDI is aiming to build a "long-term portfolio" of specialty products through licensing deals, beginning in the urology and neurology markets

PDI Combing Urology, Neurology Markets For Licensing/Acquisition Deals

PDI is aiming to build a "long-term portfolio" of specialty products through licensing deals, beginning in the urology and neurology markets

PDI Evista Lessons Learned: Firm Focuses On Smaller Contracts, No Baselines

PDI will focus on smaller contract sales opportunities in the 50-representative range following termination of the Evista promotion deal with Lilly, CEO Charles Saldarini said on a conference call Nov. 12

Related Content

UsernamePublicRestriction

Register

PS041822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel